| Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF P McEwan, O Darlington, JJV McMurray, PS Jhund, KF Docherty, M Böhm, ... European journal of heart failure 22 (11), 2147-2156, 2020 | 117 | 2020 |
| Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK C Linde, L Qin, A Bakhai, H Furuland, M Evans, D Ayoubkhani, E Palaka, ... ESC Heart Failure 6 (2), 280-290, 2019 | 74 | 2019 |
| Real‐world associations of renin–angiotensin–aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new‐onset chronic … C Linde, A Bakhai, H Furuland, M Evans, P McEwan, D Ayoubkhani, L Qin Journal of the American Heart Association 8 (22), e012655, 2019 | 63 | 2019 |
| Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study L Qin, S Chen, E Flood, A Shaunik, B Romero, M Cruz, C Alvarez, ... Diabetes Therapy, 1-14, 2017 | 51* | 2017 |
| Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink H Furuland, P McEwan, M Evans, C Linde, D Ayoubkhani, A Bakhai, ... BMC nephrology 19, 1-16, 2018 | 50 | 2018 |
| The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease M Evans, E Palaka, H Furuland, H Bennett, C Linde, L Qin, P McEwan, ... BMC nephrology 20, 1-11, 2019 | 34 | 2019 |
| Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England L Horne, A Ashfaq, S MacLachlan, M Sinsakul, L Qin, R LoCasale, ... BMC nephrology 20, 1-12, 2019 | 33 | 2019 |
| Delays in treatment intensification with oral antidiabetic drugs and risk of microvascular and macrovascular events in patients with poor glycaemic control: A n individual … HJ Folse, J Mukherjee, JJ Sheehan, AJ Ward, RL Pelkey, TA Dinh, L Qin, ... Diabetes, Obesity and Metabolism 19 (7), 1006-1013, 2017 | 21 | 2017 |
| Contemporary economic burden in a real‐world heart failure population with commercial and Medicare supplemental plans CSP Lam, R Wood, M Vaduganathan, H Bueno, A Chin, ... Clinical Cardiology 44 (5), 646-655, 2021 | 16 | 2021 |
| An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus P McEwan, H Bennett, L Qin, K Bergenheim, J Gordon, M Evans Diabetes, Obesity and Metabolism 19 (5), 628-634, 2017 | 9 | 2017 |
| Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States L Qin, X Luo, KH Zou, SJ Snedecor Journal of Medical Economics 19 (3), 229-235, 2016 | 9 | 2016 |
| Serum potassium as a predictor of adverse clinical outcomes in patients with increasing comorbidity burden E Tafesse, M Hurst, D Sugrue, L Hoskin, K Badora, L Qin, G James, ... European Heart Journal-Quality of Care and Clinical Outcomes 8 (1), 61-69, 2022 | 8 | 2022 |
| Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC Heart Fail. 2019; 6 (2): 280–90 C Linde, L Qin, A Bakhai, H Furuland, M Evans, D Ayoubkhani, E Palaka, ... Go to original source... Go to PubMed, 0 | 8 | |
| Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions E Tafesse, M Hurst, L Hoskin, K Badora, D Sugrue, L Qin, G James, ... International Journal of Clinical Practice 75 (4), e13941, 2021 | 6 | 2021 |
| Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure A Bakhai, E Palaka, C Linde, H Bennett, H Furuland, L Qin, P McEwan, ... Journal of Medical Economics 21 (12), 1172-1182, 2018 | 6 | 2018 |
| 1: CAS: 528: DC% 2BC2sXitVWhtbg% 3D: Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-naïve patients with type 2 diabetes mellitus: a … L Qin, S Chen, E Flood Diabetes Ther, 321-334, 2017 | 6 | 2017 |
| Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People’s Republic of China N Mao, B Lesher, Q Liu, L Qin, Y Chen, X Gao, SR Earnshaw, CL McDade, ... ClinicoEconomics and Outcomes Research, 275-285, 2016 | 6 | 2016 |
| Cost‐effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure RJH Miller, DS Chew, L Qin, NM Fine, J Chen, JJV McMurray, JG Howlett, ... European Journal of Heart Failure 25 (2), 238-247, 2023 | 3 | 2023 |
| Budget impact evaluation of the DAPA-HF trial: is dapagliflozin cost-saving for the treatment of heart failure with reduced ejection fraction? L Qin, O Darlington, R Miller, C Mellstrom, P Mcewan EUROPEAN JOURNAL OF HEART FAILURE 23, 305-305, 2021 | 3 | 2021 |
| Economic burden of pediatric atopic dermatitis in Asia-Pacific: a review of the literature A Bhanegaonkar, L Qin, EH Horodniceanu, X Ji, P Detzel, M Botteman Value in Health 17 (7), A778, 2014 | 3 | 2014 |
